Today, the European Commission adopted the decision granting marketing authorisation to the company Merck Sharp & Dohme B.V. for a vaccine against Ebola. This vaccine, called Ervebo, had been in development since the Ebola outbreak in West Africa in 2014. It is already used, as part of a specific protocol, to protect people at risk of infection, such as healthcare workers or people who have been exposed to infected persons.
Continue reading on the source website: https://ec.europa.eu/commission/presscorner/detail/en/ip_19_6246